Pulmonary embolism (PE) is a potentially life-threatening condition and the fact that 90% of PE originate from lower limb veins highlights the significance of early detection and treatment of deep vein thrombosis. Massive/high risk PE involving circulatory collapse or systemic arterial hypotension is associated with an early mortality rate of approximately 50%, in part from right ventricular (RV) failure. Intermediate risk/submassive PE, on the other hand, is defined as PE-related RV dysfunction, troponin and/or B-type natriuretic peptide elevation despite normal arterial pressure. Without prompt treatment, patients with intermediate risk PE may progress to the massive category with a potentially fatal outcome. In patients with PE and right ventricular dysfunction (RVD), in hospital mortality ranges from 5% to 17%, significantly higher than in patients without RVD.

Purpose: This study aims to evaluate the relationship between the platelet/lymphocyte ratio (PLR) measured at admission and the occurrence of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Materials and Methods: This study included 126 patients with acute STEMI treated with primary PCI. Hemoglobin, thrombocyte, and lymphocyte levels of the patients were retrieved from the files at the time of admission. Postprocedural thrombolysis in myocardial infarction (TIMI) flow grade, postprocedural myocardial blush grade (MBG), and TIMI thrombus scale were evaluated from the coronary angiography records. Results: Patients were divided into two groups according to TIMI flow grade after PCI as normal coronary flow (n = 66) and no-reflow groups (n = 60). The no-reflow group had lower LVEF and higher PLR compared to the normal coronary flow group PLR was significantly higher in patients with lower TIMI flow grade and MBG. Conclusion: PLR measured at admission was found to be higher in STEMI patients who developed no-reflow after primary PCI compared to the normal coronary flow group. PLR can be used as a predictor for no-reflow in such patients. Amaç: Bu çalışmanın amacı, primer perkütan koroner girişim (PKG) ile tedavi edilen akut ST-segment yükselmeli miyokard infarktüsü (STYMİ) hastalarında başvuru sırasında ölçülen platelet/lenfosit oranının (PLO) ile no-reflow fenomeni oluşumu arasındaki ilişkiyi değerlendirmektir. Gereç ve Yöntem: Bu çalışmada, primer PKG ile tedavi edilen akut STYMİ'li 126 hasta kapsanmıştırr. Hastaların hastaneye başvuru anındaki hemoglobin, trombosit ve lenfosit düzeyleri dosya verilerinden elde edildi. Hastaların işlem sonrasındaki miyokard infarktüsünde tromboliz (TIMI) akım derecesi, miyokardın boyanma derecesi (MBG) ve TIMI trombüs ölçeği koroner anjiyografi kayıtlarından değerlendirildi. Bulgular: Hastalar PKG sonrası TIMI akım derecesine göre normal koroner akım (s=66) grubu ve azalmış koroner akım (no-reflow) grubu (s=60) olmak üzere iki gruba ayrıldı. No-reflow grupta normal koroner akım grubu ile kıyaslandığında daha düşük SVEF ve daha yüksek PLO vardı. TIMI akım derecesi ve MBG' si daha düşük olan hastalarda, PLO anlamlı olarak daha yüksekti. Sonuç: Primer PKG sonrasında no-reflow gelişen STYMİ hastalarında başvuru sırasında ölçülen PLO daha yüksek saptanmıştır. PLO, bu tür hastalarda no-reflow için bir öngörürücü olarak kullanılabilir.

Background and Objectives: Systemic inflammation is a key driver in the progression and complexity of coronary artery disease (CAD). Serum calprotectin and the C-reactive protein–triglyceride–glucose index (CTI) have emerged as potential inflammatory and metabolic biomarkers; however, their association with angiographic disease severity has not been clearly defined. This study aimed to evaluate the relationship between serum calprotectin, CTI, and the SYNTAX score (SS) in patients with stable CAD. Materials and Methods: A total of 134 patients undergoing coronary angiography were enrolled. The SS was calculated to quantify coronary lesion complexity. Patients were classified into two groups based on the results of the coronary angiogram: low SS (n = 73, SS < 23), and intermediate–high SS (n = 61, SS ≥ 23). Serum calprotectin, and CTI were obtained at baseline. Correlation analyses were performed to evaluate associations between biomarkers and SS. Receiver operating characteristic (ROC) curve analysis assessed the ability of these biomarkers to predict intermediate–high SS. Univariable and multivariable logistic regression analyses were performed to determine independent associations. Results: Patients with intermediate–high SS had significantly higher levels of serum calprotectin (1009.5 vs. 505.7 ng/mL), and CTI (9.9 vs. 9.5) compared with those with low SS (all p < 0.001). Spearman correlation analysis demonstrated significant positive correlations between SS and, serum calprotectin (ρ = 0.488), and CTI (ρ = 0.453) (all p < 0.001). ROC analysis showed moderate association in respect to intermediate–high SS (0.739 for serum calprotectin, and 0.722 for CTI). In multivariable models, CTI showed the strongest independent association with intermediate–high SS (OR: 4.66, 95% CI: 2.00–10.84, p < 0.001). Conclusions: Serum calprotectin and CTI were significantly associated with coronary lesion complexity, as measured by the SS. These biomarkers may serve as valuable tools for identifying patients with greater CAD severity and anatomical complexity.

Background and Objectives: Systemic inflammation is a key driver in the progression and complexity of coronary artery disease (CAD). Serum calprotectin and the C-reactive protein–triglyceride–glucose index (CTI) have emerged as potential inflammatory and metabolic biomarkers; however, their association with angiographic disease severity has not been clearly defined. This study aimed to evaluate the relationship between serum calprotectin, CTI, and the SYNTAX score (SS) in patients with stable CAD. Materials and Methods: A total of 134 patients undergoing coronary angiography were enrolled. The SS was calculated to quantify coronary lesion complexity. Patients were classified into two groups based on the results of the coronary angiogram: low SS (n = 73, SS <23), and intermediate–high SS (n = 61, SS >23). Serum calprotectin, and CTI were obtained at baseline. Correlation analyses were performed to evaluate associations between biomarkers and SS. Receiver operating characteristic (ROC) curve analysis assessed the ability of these biomarkers to predict intermediate–high SS. Univariable and multivariable logistic regression analyses were performed to determine independent associations. Results: Patients with intermediate–high SS had significantly higher levels of serum calprotectin (1009.5 vs. 505.7 ng/mL), and CTI (9.9 vs. 9.5) compared with those with low SS (all p<0.001). Spearman correlation analysis demonstrated significant positive correlations between SS and, serum calprotectin (ρ = 0.488), and CTI (ρ = 0.453) (all p < 0.001). ROC analysis showed moderate discriminatory performance for predicting intermediate–high SS (0.739 for serum calprotectin, and 0.722 for CTI). In multivariable models, CTI showed the strongest independent association with intermediate–high SS (OR: 4.66, 95% CI: 2.00–10.84, p<0.001). Conclusions: Serum calprotectin and CTI were significantly associated with coronary lesion complexity, as measured by the SS. These biomarkers may serve as valuable tools for identifying patients with greater CAD severity and anatomical complexity.